Copertina

Second Therapeutic Freeze After Salvage Cryoablation for Localized Radiorecurrent Prostate Cancer

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Sudharshanan Balaji, Mahdi Mottaghi, Paul P. Koffer, Thomas J. Polascik
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Perioperative Safety and Early Oncologic Outcomes of Salvage Irreversible Electroporation for Radiorecurrent Prostate Cancer
di: Jarrett Noakes, et al.
Pubblicazione: (2026)

Image‐guided multiparametric magnetic resonance imaging‐transrectal ultrasound fusion biopsy augmented with a sextant versus an extended template random biopsy: Comparison of cancer detection rates, complication and functional outcomes
di: Eric S. Adams, et al.
Pubblicazione: (2024)

Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
di: Emily Chan, et al.
Pubblicazione: (2025)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
di: Elizabeth Robinson, et al.
Pubblicazione: (2025)

Genetics‐Driven, Intensity‐Modulated Adaptive Management of Patients With Metastatic Prostate Cancer
di: Reynier D. Rodriguez Rosales, et al.
Pubblicazione: (2025)

Genomic and Clinical Impact of Smoking on Therapeutic Outcomes in Prostate Cancer: A Public Databases Analysis
di: Tomoya Hatayama, et al.
Pubblicazione: (2026)

Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy
di: Victor Sandoval, et al.
Pubblicazione: (2025)

Hormone Therapy With Salvage Radiotherapy After Radical Prostatectomy: A Systematic Review and Meta‐Analysis
di: Reyhaneh Bayani, et al.
Pubblicazione: (2025)

Outcome Differences Between Subgroups of Favorable Intermediate Risk Prostate Cancer After Radical Prostatectomy
di: Matthew T. Steidle, et al.
Pubblicazione: (2026)

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer
di: William Lautert‐Dutra, et al.
Pubblicazione: (2026)

Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer
di: Trevor C. Hunt, et al.
Pubblicazione: (2025)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
di: Fabian Falkenbach, et al.
Pubblicazione: (2025)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
di: Meryam Losee, et al.
Pubblicazione: (2025)

The Role of Secondary Lesion Biopsy in Detecting Clinically Significant Prostate Cancer
di: Trevor C. Hunt, et al.
Pubblicazione: (2025)

CHARGE: The “Big Questions” in Prostate Cancer for 2024
di: Andrea K. Miyahira, et al.
Pubblicazione: (2024)

Pathology of a Canine Model of Localized Prostate Carcinoma
di: Nathan K. Hoggard, et al.
Pubblicazione: (2025)

LHRH Antagonists Restore Serum Testosterone Faster Than LHRH Agonists in Prostate Cancer Patients After Radiotherapy
di: Sangjon Pae, et al.
Pubblicazione: (2025)

Surveillance Versus Treatment for Favorable Intermediate‐Risk Prostate Cancer and Mortality‐Risk
di: Mutlay Sayan, et al.
Pubblicazione: (2026)

Castration Resistance Accelerates Prostate Cancer Kinetics
di: Sheila Jonnatan, et al.
Pubblicazione: (2026)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
di: Tatsuya Shimomura, et al.
Pubblicazione: (2026)

Developments in Ultrasound‐Based Imaging for Prostate Cancer Detection
di: Reid Vassallo, et al.
Pubblicazione: (2025)

Evidence and Rationale for Prostate Cancer Screening
di: Takeshi Takahashi
Pubblicazione: (2025)

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
di: András Horváth, et al.
Pubblicazione: (2025)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
di: Kotaro Suzuki, et al.
Pubblicazione: (2026)

Enhancing Prostate Cancer Diagnosis: The Combined Value of PHI and mpMRI
di: Y. M. Yáñez‐Castillo, et al.
Pubblicazione: (2025)

Altered Glycosylation of PSA in Prostate Cancer Tissue
di: Hannu Koistinen, et al.
Pubblicazione: (2025)

Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study
di: Cameron J. Britton, et al.
Pubblicazione: (2025)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
di: Christian P. Pavlovich, et al.
Pubblicazione: (2025)

[ 18 F] PSMA PET‐CT and [ 18 F] Choline PET‐CT in the Diagnosis of High‐Risk Localized Prostate Cancer: Comparation of Both Tests
di: M. A. Tárraga‐Honrubia, et al.
Pubblicazione: (2026)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
di: Yifu Shi, et al.
Pubblicazione: (2025)

Factors Associated With Male Breast Cancer Incidence Among Prostate Cancer Survivors: Real World Evidence From Veterans Affairs National Prostate Cancer Data Core
di: Erum Z. Whyne, et al.
Pubblicazione: (2025)

Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity
di: Yasushi Nakai, et al.
Pubblicazione: (2025)

Relationship Between Radiation Therapy and Fecal Incontinence in Patients Treated for Localized Prostate Cancer: Results of the French ICONES Study
di: Yazid Belkacemi, et al.
Pubblicazione: (2025)

Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
di: Masanori Ishida, et al.
Pubblicazione: (2025)

Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms
di: Charly Bâcle, et al.
Pubblicazione: (2025)

The Diagnostic Value of Plasma Small Extracellular Vesicle‐Derived CAIX Protein in Prostate Cancer and Clinically Significant Prostate Cancer: A Study on Predictive Models
di: Haotian Chen, et al.
Pubblicazione: (2025)

Survival Outcomes for Rural Patients With Advanced Prostate Cancer: A SEER Investigation
di: Liang G. Qu, et al.
Pubblicazione: (2025)

Prostate Volume and PSA‐Density Estimation by Transabdominal Ultrasound: Prospective Evidence of Comparative Accuracy to MRI and Transrectal Ultrasound in Prostate Cancer Early Diagnostics
di: Liza M. Kurucz, et al.
Pubblicazione: (2025)

Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics
di: Kristofer G. Taylor, et al.
Pubblicazione: (2026)

Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer Treatment
di: Muhammad Umair, et al.
Pubblicazione: (2026)